glp 1 agonists vs sglt2 inhibitors Frontiers Cardiovascular benefits of SGLT2 inhibitors

According to Lilly, retatrutide is not yet available to the public, is not FDA-approved, and is still being studied in Phase 3 trials

Instead, the Lancet Commission is looking to define more appropriate, scientifically sound and pragmatic criteria for the diagnosis of clinical obesity as a disease state, not a risk factor

The report includes an executive summary and a comprehensive overview of market drivers, restraints, opportunities, and challenges (DROC), along with insights into regulatory standards

Increased levels of cytokines such as IL-6, IL-8, IL-1, TNF-, and IFN- as well as chemokines including chemokine receptor 2 (CCR2), C-C motif chemokine ligand 2 (CCL2), CCL5 (RANTES), and C-X-C motif chemokine ligand 10 (CXCL10) have been observed in kidney tissue of rodent models of diabetes, as well as in plasma and serum of people with DKD (43)

doi: 10.1111/jdv.12629

Lessons from clinical trials demonstrate these effects are mainly driven by reductions in albuminuria